Why diabetic nerve damage can start years before a diabetes diagnosis
A person can have numbness, tingling, or burning in their feet for years before any blood test shows they are diabetic. Sometimes a decade. The standard story is that diabetes causes nerve damage over time. The nerve symptoms should show up after the diagnosis. The research describes something different. The damage often starts during the years when blood sugar is drifting upward but still in the normal range. That can be years before a lab catches it.
This article walks through what the studies actually show. We will cover four pieces of the picture. How long type 2 diabetes is usually present before it is diagnosed. What nerve studies find in people with prediabetes. The proposed mechanism of why nerves are affected so early. And what current research says about prevention versus reversal. This is education, not medical advice. Anyone with new or persistent nerve symptoms should talk to their doctor.
Type 2 diabetes is older than its diagnosis
Type 2 diabetes does not start the day a doctor calls a patient with the result. It starts much earlier. The body's response to insulin begins to slip. The pancreas works harder to compensate. Fasting glucose drifts upward. For years, the numbers stay just under the line a routine test is looking for.
A landmark 1992 paper by Harris and colleagues in Diabetes Care analyzed two large populations of newly diagnosed patients. The authors concluded that the onset of type 2 diabetes occurs at least 4 to 7 years before clinical diagnosis.1 More recent work has refined the picture. The Whitehall II study, published in The Lancet in 2009, tracked 6,538 British civil servants over nearly a decade. During follow-up, 505 of them developed type 2 diabetes.2
The researchers tracked their glucose over time. Fasting glucose drifted upward gradually for years. Then a steeper rise began about three years before diagnosis. Numbers climbed from roughly 5.79 mmol/L (about 104 mg/dL) to 7.40 mmol/L (about 133 mg/dL) in those final years.2 Insulin sensitivity dropped over a similar window. The disease was busy for a long time before it announced itself.
By the time someone is told they have type 2 diabetes, the body has been operating with mildly elevated blood sugar for several years. The clock on whatever damage that elevated sugar can do has been running the whole time.
Nerves don't wait for the threshold
If glucose is elevated for years before diagnosis, the question becomes whether nerves register it during those years. The research suggests they do.
A 2021 systematic review in BMJ Open Diabetes Research & Care pooled 29 studies covering 9,351 participants with prediabetes. The reported prevalence of peripheral neuropathy varied widely, from 2% to 77%, depending on how it was measured. The majority of studies — 21 out of 29 — found a prevalence of at least 10%.3 The variability is real and worth understanding. It comes mostly from differences in testing methods.
Standard nerve conduction studies measure large nerve fibers. These are the fibers that handle vibration and body position. Small fibers handle pain and temperature. They also produce the burning or tingling sensation that often comes first. Routine tests don't pick up small-fiber problems. Studies that used small-fiber methods consistently found higher prevalence of nerve abnormalities in prediabetes than studies that used large-fiber methods.3 The reviewers concluded that peripheral neuropathy in prediabetes is "primarily of a small nerve fiber origin."
A 2015 study in Diabetes Care by Azmi and colleagues at the University of Manchester showed this directly. The researchers used corneal confocal microscopy. This is a non-invasive technique that images the small nerves of the cornea. They scanned 30 people with impaired glucose tolerance. Ten of those participants went on to develop type 2 diabetes during three years of follow-up. At baseline, before they crossed the diagnostic threshold, those ten already had measurably lower corneal nerve fiber density than healthy controls (P=0.003).4 In other words, the nerve damage was already there. The diabetes label arrived later.
The nerves get the message before the bloodstream announces it loudly enough.
This is the part that doesn't make it into most clinical conversations. The lab doesn't catch it because the lab wasn't designed to.
The proposed mechanism
Why are nerves affected so early? The answer involves several biochemical pathways. They activate when glucose levels are higher than the body is designed to handle. This can happen even when glucose is still below the threshold for a diabetes diagnosis. A 2024 review in Frontiers in Endocrinology describes the main pathways currently discussed in the literature.5
The polyol pathway is one of the most studied. Under normal conditions, almost all the glucose entering a cell goes through standard glycolysis. Under high-glucose conditions, an enzyme called aldose reductase becomes more active. It starts shunting glucose into a different pathway, converting it to sorbitol. A 2021 review in the International Journal of Molecular Sciences by Niimi and colleagues describes how this affects nerves. Aldose reductase is highly expressed in Schwann cells. These are the support cells that wrap around nerve fibers. When the enzyme is overactive, sorbitol builds up inside these cells. The process also depletes NADPH, a molecule the cell uses to defend against oxidative stress. The result is osmotic disruption and reduced antioxidant capacity. Both are bad for the support cells around nerve fibers.6
A second pathway involves what are called advanced glycation end products, or AGEs. These form when sugar molecules bind to proteins and lipids in the body. A 2008 review in Current Pharmaceutical Design by Sugimoto and colleagues described several ways AGEs affect peripheral nerves. AGEs change the myelin around nerve fibers. Myelin is the insulating layer the body wraps around nerves to help them work. Once myelin is changed by AGEs, the immune system is more likely to attack and break it down. AGEs also bind to a receptor called RAGE. That binding triggers inflammation and oxidative stress in nerve tissue. Over months and years of elevated glucose, this damage adds up.7
A third part of the picture is the small blood vessels that feed the nerves themselves. Nerves require their own blood supply, delivered through tiny vessels called the vasa nervorum. A 2001 review in Diabetologia by Cameron and colleagues summarized the structural changes seen in nerve biopsies from diabetic patients. These included thickening of the basement membrane around small vessels, breakdown of supporting cells called pericytes, and overgrowth of the cells lining those vessels. The combined effect is reduced nerve perfusion and endoneurial hypoxia. In plain language: too little blood flow, and too little oxygen reaching the inner core of the nerve.8 Whether these vascular changes start the damage or follow from it is still being worked out.
These pathways overlap. They produce reactive oxygen species. They damage the supporting cells around nerve fibers. They impair the structural proteins that keep axons functioning. The result is a slow, progressive injury to nerve fibers. It begins during the prediabetic years. It continues afterward unless something interrupts it.
"Newly diagnosed" is not "new"
Once a person is told they have type 2 diabetes, the damage assessment becomes meaningful. A 2014 study in the International Journal of Endocrinology examined microvascular complications in newly diagnosed type 2 patients. It found that 8.2% already had neuropathy at the time of diagnosis. About 9.5% had retinopathy. About 2.8% had nephropathy.9
A 2024 review in Frontiers in Endocrinology puts the number for nerve damage somewhat higher. It cites studies finding that 10-15% of newly diagnosed type 2 patients have distal symmetric polyneuropathy at the moment of diagnosis. After ten years with the disease, the prevalence exceeds 50%.5 Different studies report different numbers. They use different definitions and different tests. But the general direction is consistent. A meaningful fraction of people are walking into their diagnosis with detectable nerve injury already in progress.
The phrase "newly diagnosed" tends to be heard as "new disease." It isn't. It's new to the medical record. The disease itself is older.
What does this mean for prevention and reversal
The honest answer is that prevention and reversal are different questions. The research treats them differently.
A 2014 review in Current Diabetes Reports examined the major glycemic-control trials. The authors concluded that tight glycemic control is the only strategy convincingly shown to prevent or delay neuropathy in type 1 diabetes. It also slows the progression of neuropathy in some patients with type 2 diabetes. The review was explicit that whether good glycemic control can reverse preexisting nerve damage in type 2 diabetes remains unproven.10
That distinction matters. Catching elevated glucose early and bringing it down may slow or prevent the kind of nerve injury described above. Reversing damage that has already occurred is harder. The evidence for reversal is less clear. There are some signals. The Azmi study found that participants who returned to normal glucose tolerance over three years showed improvement in corneal nerve fiber density.4 That suggests early small-fiber injury may have some capacity to recover. But this was a small group within a small study. Large clinical trials in established type 2 diabetes have generally not shown reversal of measurable nerve damage from glycemic control alone.
The practical takeaway is this. A person who has just been diagnosed with type 2 diabetes has more options for slowing future damage than for undoing what has already happened. The same is true of someone in the prediabetic range wondering whether their occasional foot tingling is meaningful. That is not the same as saying nothing can be done. It means the window of strongest leverage is before symptoms become entrenched. And that window often opens earlier than the diagnosis.
This article is education, not medical advice. Anyone with persistent nerve symptoms should talk to their doctor about whether further evaluation is worth pursuing. Tingling, burning, numbness, sensitivity changes — these are worth bringing up. The conversation is more useful when both the patient and the doctor understand what the research actually shows. Decisions about medications or monitoring are clinical questions for that conversation, not for an article.
The honest summary
Type 2 diabetes is typically present for years before a doctor diagnoses it. During those years, fasting glucose climbs upward. Insulin sensitivity falls. Several biochemical pathways begin to affect nerve tissue. The nerves can register this before the bloodstream registers it loudly enough for routine tests to flag.
This is not a story about a sudden break. It is a story about a gradual one. It takes place inside the normal-looking lab range, often invisible until symptoms force attention. The research describing it has existed for decades. It just hasn't become part of the conversation most patients have with their doctors.
There is a useful question that follows from all this. Suppose a person notices new or unusual symptoms in their feet or hands — tingling, burning, numbness, sensitivity that wasn't there before. Suppose their fasting glucose is "in range" but trending upward. That combination is information worth bringing to a doctor. Not as a diagnosis. As a question.
The research is the research. What to do with it is a clinical question.
- Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815-819. https://diabetesjournals.org/care/article/15/7/815/17655/
- Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221. https://pubmed.ncbi.nlm.nih.gov/19515410/
- Kirthi V, Perumbalath A, Brown E, et al. Prevalence of peripheral neuropathy in pre-diabetes: a systematic review. BMJ Open Diabetes Research & Care. 2021;9(1):e002040. https://pmc.ncbi.nlm.nih.gov/articles/PMC8137250/
- Azmi S, Ferdousi M, Petropoulos IN, et al. Corneal Confocal Microscopy Identifies Small-Fiber Neuropathy in Subjects With Impaired Glucose Tolerance Who Develop Type 2 Diabetes. Diabetes Care. 2015;38(8):1502-1508. https://pmc.ncbi.nlm.nih.gov/articles/PMC4512140/
- Zhu J, Hu Z, Luo Y, et al. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Frontiers in Endocrinology (Lausanne). 2024;14:1265372. https://pmc.ncbi.nlm.nih.gov/articles/PMC10803883/
- Niimi N, Yako H, Takaku S, Chung SK, Sango K. Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems. International Journal of Molecular Sciences. 2021;22(3):1031. https://pmc.ncbi.nlm.nih.gov/articles/PMC7864348/
- Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Current Pharmaceutical Design. 2008;14(10):953-961. https://pubmed.ncbi.nlm.nih.gov/18473845/
- Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44(11):1973-1988. https://pubmed.ncbi.nlm.nih.gov/11719828/
- Bansal D, Gudala K, Esam HP, Nayakallu R, Vyamusani RV, Bhansali A. Microvascular Complications and Their Associated Risk Factors in Newly Diagnosed Type 2 Diabetes Mellitus Patients. International Journal of Endocrinology. 2014;2014:201423. https://pmc.ncbi.nlm.nih.gov/articles/PMC4590918/
- Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Current Diabetes Reports. 2014;14(9):528. https://pmc.ncbi.nlm.nih.gov/articles/PMC5084623/